Results 21 to 30 of about 1,579,650 (291)

Supporting data for "Immunophenotyping of anti-PD-L1-treated hepatocellular carcinoma"

open access: yes, 2023
Hepatocellular carcinoma (HCC) is a deadly disease. The FDA recently approved the first immunotherapy, atezolizumab (anti-PD-L1) plus bevacizumab (anti-VEGF-A), for advanced HCC. Nonetheless, there are still patients not responding.
Fu Wan Sit (11211570)
core   +1 more source

Serum immune mediators as novel predictors of response to anti-PD-1/PD-L1 therapy in non-small cell lung cancer patients with high tissue-PD-L1 expression [PDF]

open access: yes, 2023
Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related morbidity and mortality worldwide. Immune checkpoint inhibitors (ICIs) including anti-PD-1 and anti-PD-L1 antibodies, have significantly changed the treatment outcomes with better ...
Raza, Afsheen   +45 more
core   +1 more source

PD-L1 Expression in Mastocytosis [PDF]

open access: yesInternational Journal of Molecular Sciences, 2019
Programmed death 1 (PD-1), when activated by its ligands PD-L1 and PD-L2, suppresses active immune cells in normal immune regulation to limit autoimmunity and, in tumors, as a mechanism of immune evasion. PD-L1 expression has been described as both a prognostic and predictive marker in many solid and hematologic neoplasms, as targeted therapies against
Margaret Williams   +3 more
openaire   +4 more sources

Establishment of Human PD-1/PD-L1 Blockade Assay Based on Surface Plasmon Resonance (SPR) Biosensor

open access: yesBio-Protocol, 2023
Blockade of the programmed cell death protein 1 (PD-1)/PD-ligand 1 (PD-L1) axis is a promising strategy for cancer immunotherapy. Although antibody-based PD-1/PD-L1 inhibitors have shown remarkable results in clinical cancer studies, their inherent ...
Tess Puopolo   +6 more
doaj   +1 more source

PD-L1 sensitivity and specificity of antibody clone 29E.2A3 for PD-L1.

open access: yes, 2021
A.Western blot of cell lysates from cultured human breast cancer cell lines known to express (MDA-MB-231) or not to express PD-L1 (MCF-7) using E1L3N Rabbit mAb, confirming the PD-L1 status of these two cell lines. B.
James M. Rae (7876037)   +15 more
core   +1 more source

The CTLA-4 and PD-1/PD-L1 inhibitory pathways independently regulate host resistance to Plasmodium-induced acute immune pathology. [PDF]

open access: yes, 2012
The balance between pro-inflammatory and regulatory immune responses in determining optimal T cell activation is vital for the successful resolution of microbial infections.
Couper, Kevin N   +44 more
core   +1 more source

Western Blot PD-L1 expression after XVir-N-31-anti-PD-L1 infection.pdf

open access: yes, 2022
PD-L1 expression of HEK cells after XVir-N-31-anti-PD-L1 infection.
Moritz Klawitter (13177230)
core   +1 more source

Binding and inhibition assays of anti-PD-L1 antibody.

open access: yes, 2022
(A) Specific binding to human PD-L1 by ELISA. The Tecentriq® and human IgG1 was used as positive and negative control respectively. Plant-produced anti-PD-1 antibody was also used to confirm the non-specificity to PD-L1.
Thareeya Phetphoung (14106521)   +11 more
core   +1 more source

Programmed Cell Death Ligand 1 Is Enriched in Mammary Stem Cells and Promotes Mammary Development and Regeneration

open access: yesFrontiers in Cell and Developmental Biology, 2021
Programmed cell death ligand 1 (PD-L1) is widely expressed in a variety of human tumors, and inhibition of the PD-L1/PD-1 pathway represents one of the most promising therapy for many types of cancer.
Ruirui Wang   +8 more
doaj   +1 more source

Tumor cells versus host immune cells: whose PD-L1 contributes to PD-1/PD-L1 blockade mediated cancer immunotherapy?

open access: yesCell & Bioscience, 2018
Antibody blockade of the PD-1/PD-L1 pathway has elicited durable antitumor responses in the therapy of a broad spectrum of cancers. PD-L1 is constitutively expressed in certain tumors and host immune cells, and its expression can be induced or maintained
Fei Tang, Pan Zheng
doaj   +1 more source

Home - About - Disclaimer - Privacy